OSIR SEC Filings - Osiris Therapeutics, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

1360886

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Osiris Therapeutics, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

April 29, 2019	15-12B	OSIR / Osiris Therapeutics, Inc. 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-32966 Osiris Therapeutics, Inc. (Exact name of registrant as specified i
April 17, 2019	S-8 POS	OSIR / Osiris Therapeutics, Inc. S-8 POS As filed with the Securities and Exchange Commission on April 17, 2019 Registration No.
April 17, 2019	S-8 POS	OSIR / Osiris Therapeutics, Inc. S-8 POS As filed with the Securities and Exchange Commission on April 17, 2019 Registration No.
April 17, 2019	S-8 POS	OSIR / Osiris Therapeutics, Inc. S-8 POS As filed with the Securities and Exchange Commission on April 17, 2019 Registration No.
April 17, 2019	S-8 POS	OSIR / Osiris Therapeutics, Inc. S-8 POS As filed with the Securities and Exchange Commission on April 17, 2019 Registration No.
April 17, 2019	S-8 POS	OSIR / Osiris Therapeutics, Inc. S-8 POS As filed with the Securities and Exchange Commission on April 17, 2019 Registration No.
April 17, 2019	EX-99.1	Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc Exhibit 99.1 Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc COLUMBIA, Md., April 17, 2019 — Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has completed the previously announced sale of Osiris to Smith & Nephew plc (“Smi
April 17, 2019	EX-3.1	Amended and Restated Articles of Incorporation of the Company. Exhibit 3.1 OSIRIS THERAPEUTICS, INC. ARTICLES OF AMENDMENT AND RESTATEMENT FIRST: Osiris Therapeutics, Inc., a Maryland corporation (the “Corporation”), desires to and does hereby amend and restate in its entirety the charter of the Corporation (the “Charter”) as currently in effect. SECOND: The following provisions are all the provisions of the Charter currently in effect, as amended and restate
April 17, 2019	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2019 OSIRIS THERAPEUTICS, INC.
April 17, 2019	EX-3.2	Amended and Restated Bylaws of the Company. Exhibit 3.2 OSIRIS THERAPEUTICS, INC. BYLAWS ARTICLE I OFFICES Section 1. PRINCIPAL OFFICE. The principal office of the Corporation in the State of Maryland shall be located at such place as the Board of Directors may designate. Section 2. ADDITIONAL OFFICES. The Corporation may have additional offices, including a principal executive office, at such places as the Board of Directors may from time
April 17, 2019	SC TO-T/A	SNN / Smith & Nephew PLC SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) OSIRIS THERAPEUTICS, INC. (Name of Subject Company) PAPYRUS ACQUISITION CORP. (Offeror) SMITH & NEPHEW CONSOLIDATED, INC. SMITH & NEPHEW PLC (Parent of Offeror) (Names of Filing Persons) Common s
April 17, 2019	SC 14D9/A	OSIR / Osiris Therapeutics, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Osiris Therapeutics, Inc. (Name of Subject Company) Osiris Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur
April 16, 2019	SC 14D9/A	OSIR / Osiris Therapeutics, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Osiris Therapeutics, Inc. (Name of Subject Company) Osiris Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur
April 12, 2019	SC TO-T/A	SNN / Smith & Nephew PLC SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) OSIRIS THERAPEUTICS, INC. (Name of Subject Company) PAPYRUS ACQUISITION CORP. (Offeror) SMITH & NEPHEW CONSOLIDATED, INC. SMITH & NEPHEW PLC (Parent of Offeror) (Names of Filing Persons) Common s
April 10, 2019	SC 14D9/A	OSIR / Osiris Therapeutics, Inc. SC 14D9/A SC 14D9/A 1 a19-81471sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Osiris Therapeutics, Inc. (Name of Subject Company) Osiris Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per sh
April 10, 2019	SC TO-T/A	SNN / Smith & Nephew PLC SC TO-T/A SC TO-T/A 1 a2238422zscto-ta.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) OSIRIS THERAPEUTICS, INC. (Name of Subject Company) PAPYRUS ACQUISITION CORP. (Offeror) SMITH & NEPHEW CONSOLIDATED, INC. SMITH & NEPHEW PLC (Parent of
March 27, 2019	SC TO-T/A	SNN / Smith & Nephew PLC SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) OSIRIS THERAPEUTICS, INC. (Name of Subject Company) PAPYRUS ACQUISITION CORP. (Offeror) SMITH & NEPHEW CONSOLIDATED, INC. SMITH & NEPHEW PLC (Parent of Offeror) (Names of Filing Persons) Common s
March 27, 2019	SC 14D9/A	OSIR / Osiris Therapeutics, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Osiris Therapeutics, Inc. (Name of Subject Company) Osiris Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 68827R10
March 20, 2019	SC 14D9	OSIR / Osiris Therapeutics, Inc. SC 14D9 SC 14D9 1 a2238152zsc14d9.htm SC 14D9 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Osiris Therapeutics, Inc. (Name of Subject Company) Osiris Therapeutics, Inc.
March 20, 2019	EX-99.(E)(3)	TENDER AND SUPPORT AGREEMENT Exhibit (e)(3) TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of March 12, 2019, is entered into by and among Smith & Nephew Consolidated, Inc.
March 20, 2019	EX-99.(A)(1)(B)	Letter of Transmittal to Tender Shares of Common Stock OSIRIS THERAPEUTICS, INC. at $19.00 Net Per Share in Cash Pursuant to the Offer to Purchase dated March 20, 2019 by PAPYRUS ACQUISITION CORP., a direct wholly-owned subsidiary of SMITH & NEPHEW C QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of OSIRIS THERAPEUTICS, INC.
March 20, 2019	EX-99.(A)(1)(C)	Notice of Guaranteed Delivery To Tender Shares of Common Stock of Osiris Therapeutics, Inc. a Maryland corporation $19.00 Net Per Share Pursuant to the Offer to Purchase Dated March 20, 2019 Papyrus Acquisition Corp. a direct wholly-owned subsidiary QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(C) Notice of Guaranteed Delivery To Tender Shares of Common Stock of Osiris Therapeutics, Inc.
March 20, 2019	EX-99.(A)(1)(F)	This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares. The Offer is made solely pursuant to the Offer to Purchase and the related Letter of Transmittal, each dated March 20, 2019. The Offer is not being made Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares.
March 20, 2019	SC TO-T	SNN / Smith & Nephew PLC SC TO-T QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
March 20, 2019	EX-99.(D)(3)	TENDER AND SUPPORT AGREEMENT Exhibit (d)(3) TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of March 12, 2019, is entered into by and among Smith & Nephew Consolidated, Inc.
March 20, 2019	EX-99.(D)(2)	MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT Exhibit (d)(2) MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT THIS MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT (“Agreement”) is effective this 12th day of July, 2018 (“Effective Date”) by and between OSIRIS THERAPEUTICS, INC.
March 20, 2019	EX-99.(A)(1)(D)	Letter to Brokers and Dealers with Respect to Offer to Purchase for Cash All Outstanding Shares of Common Stock of Osiris Therapeutics, Inc. a Maryland corporation at $19.00 Net Per Share Pursuant to the Offer to Purchase Dated March 20, 2019 by Papy QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(D) Letter to Brokers and Dealers with Respect to Offer to Purchase for Cash All Outstanding Shares of Common Stock of Osiris Therapeutics, Inc.
March 20, 2019	EX-99.(A)(1)(E)	Letter to Clients with Respect to Offer to Purchase for Cash All Outstanding Shares of Common Stock of Osiris Therapeutics, Inc. a Maryland corporation at $19.00 Net Per Share Pursuant to the Offer to Purchase Dated March 20, 2019 by Papyrus Acquisit QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(E) Letter to Clients with Respect to Offer to Purchase for Cash All Outstanding Shares of Common Stock of Osiris Therapeutics, Inc.
March 20, 2019	EX-99.(A)(1)(A)	Offer to Purchase for Cash All Outstanding Shares of Common Stock of Osiris Therapeutics, Inc. at $19.00 Net Per Share Papyrus Acquisition Corp. a direct wholly owned subsidiary of Smith & Nephew Consolidated, Inc. Use these links to rapidly review the document TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Osiris Therapeutics, Inc.
March 15, 2019	EX-31.2.1	Certification of Chief Financial Officer pursuant to Rule 13a‑14(a) or Rule 15d‑14(a) (filed herewith). Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes‑Oxley Act of 2002 I, Joel Rogers, certify that: 1. I have reviewed this Annual Report on Form 10‑K of Osiris Therapeutics, Inc., the Registrant; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state
March 15, 2019	EX-32.1.1	Section 1350 Certification of Chief Executive Officer and Chief Financial Officer (filed herewith). Exhibit 32.1.1 Certification Pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) Pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Osiris Therapeutics, Inc., (the “Company”), do
March 15, 2019	EX-21	List of Subsidiaries (filed herewith). Exhibit 21 LIST OF SUBSIDIARIES The following is a list of subsidiaries of the Company as of December 31, 2018. Jurisdiction of Name of Subsidiary Incorporation or Organization Osiris Therapeutics International GmbH Switzerland
March 15, 2019	10-K	OSIR / Osiris Therapeutics, Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10‑K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to Commission file number 001‑32966 Osiris Th
March 15, 2019	EX-23.1.1	Consent of Ernst & Young LLP (filed herewith). Exhibit 23.1.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S‑8 No. 333‑199132) pertaining to Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan, (2) Registration Statement (Form S‑8 No. 333‑184838) pertaining to Osiris Therapeutics, Inc. Amended and Res
March 15, 2019	EX-10.1.4	Form of Stock Option Award Agreement under the 2006 Omnibus Plan (filed herewith) Exhibit 10.1.4 Osiris Therapeutics, Inc. Stock Option Award Agreement Terms and Conditions This Stock Option Award Agreement, along with the Osiris Therapeutics, Inc. Stock Option Award Summary delivered herewith (the “Award Summary”), once signed by the individual named on the Award Summary (the “Participant”), shall constitute an Agreement made as of the Grant Date (as indicated on the Award Sum
March 15, 2019	EX-31.1.1	Certification of Chief Executive Officer pursuant to Rule 13a‑14(a) or Rule 15d‑14(a) (filed herewith). Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes‑Oxley Act of 2002 I, Samson Tom, certify that: 1. I have reviewed this Annual Report on Form 10‑K of Osiris Therapeutics, Inc., the Registrant; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem
March 12, 2019	SC14D9C	OSIR / Osiris Therapeutics, Inc. SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Osiris Therapeutics, Inc. (Name of Subject Company) Osiris Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 68827R108 (
March 12, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2019 OSIRIS THERAPEUTICS, INC.
March 12, 2019	EX-2.1	Agreement and Plan of Merger, dated as of March 12, 2019, by and among Smith & Nephew plc, Smith & Nephew Consolidated, Inc., Papyrus Acquisition Corp. and Osiris Therapeutics, Inc.* Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among SMITH & NEPHEW CONSOLIDATED, INC., PAPYRUS ACQUISITION CORP., OSIRIS THERAPEUTICS, INC. and SMITH & NEPHEW PLC dated as of March 12, 2019 TABLE OF CONTENTS Page ARTICLE I The Offer 2 SECTION 1.01 THE OFFER 2 SECTION 1.02 COMPANY ACTIONS 5 SECTION 1.03 DIRECTORS 6 ARTICLE II The Merger 7 SECTION 2.01 THE MERGER 7 SECTION 2.02 C
March 12, 2019	EX-99.1	ENDS Exhibit 99.1 Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc 12 March 2019 Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc. (NASDAQ: OSIR), a fast growing company delivering regenerative medicine products, including skin, bone graft and
March 12, 2019	SC TO-C	SNN / Smith & Nephew PLC SC TO-C SC TO-C 1 a19-63611sctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OSIRIS THERAPEUTICS, INC. (Name of Subject Company) PAPYRUS ACQUISITION CORP. (Offeror) SMITH & NEPHEW CONSOLIDATED, INC. SMITH & NEPHEW PLC (Parent of Offeror) (Names of Filin
March 12, 2019	EX-99.2	Smith & Nephew Agreement to acquire Osiris Therapeutics, Inc Exhibit 99.2 Smith & Nephew Agreement to acquire Osiris Therapeutics, Inc Forward looking statements and non-IFRS measures Cautionary Statement Regarding Forward Looking Statements This document contains forward-looking information related to Smith & Nephew, Osiris and the proposed transaction that involves substantial risks and uncertainties that could cause actual results to differ materially fr
March 12, 2019	SC14D9C	OSIR / Osiris Therapeutics, Inc. SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Osiris Therapeutics, Inc. (Name of Subject Company) Osiris Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 68827R108 (
March 12, 2019	EX-99.2	2 Exhibit 99.2 Osiris CEO Message to Employees To: Osiris Employees From: Samson Tom Team, I am pleased to announce that Smith & Nephew has signed a definitive agreement to acquire Osiris. This is exciting news as this acquisition will align our innovative placental technology and regenerative medicine portfolio with Smith & Nephew, a portfolio medical technology business with leadership positions i
March 12, 2019	EX-99.1	Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc Exhibit 99.1 Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc COLUMBIA, MARYLAND, Mar. 12, 2019 — Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that it has entered into an agreement and plan of merger with Smith & Nephew plc pursu
March 12, 2019	EX-99.3	2 Exhibit 99.3 FREQUENTLY ASKED QUESTIONS OSIRIS EMPLOYEES · When can we expect this acquisition to close? We hope to close in Q2. · Will there be any job reductions as part of this acquisition? This is a common concern with any acquisition. The immediate focus is to limit disruption for either Osiris or Smith & Nephew. Following that, the plan is a measured integration of Osiris into the Smith & Ne
March 12, 2019	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a19-634518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2019 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of i
November 26, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 a18-4066718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2018 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction
November 8, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2018 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of incorporation) (Commission
November 8, 2018	EX-99.1	IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND (Baltimore Division) Exhibit 99.1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND (Baltimore Division) TODD SALLEY Plaintiff, derivatively on behalf of OSIRIS THERAPEUTICS, INC., Nominal Defendant v. LODE DEBRANDERE, et al., Defendants * * * * * * Civil Action No. 17-cv-03777 * * * * * * * * * * * * * * * * * * * * * * * * SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF SHAREHOLDER DERIVATIVE AC
November 7, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2018 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of incorporation) (Commission
November 7, 2018	EX-99.1	OSIRIS THERAPEUTICS, INC REPORTS THIRD QUARTER 2018 RESULTS Exhibit 99.1 OSIRIS THERAPEUTICS, INC REPORTS THIRD QUARTER 2018 RESULTS COLUMBIA, MARYLAND, November 7, 2018 (GLOBE NEWSWIRE) - Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today reported its results for the third quarter ending September 30, 2018. Business Highlights · Graf
November 7, 2018	10-Q	OSIR / Osiris Therapeutics, Inc. 10-Q (Quarterly Report) 10-Q 1 osir-20180930x10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu
September 17, 2018	EX-99.1	Diane Savoie Osiris Therapeutics, Inc. (443) 545-1834 Exhibit 99.1 Osiris Therapeutics, Inc. Announces GrafixPL PRIME™ Launches October 1, 2018 COLUMBIA, MARYLAND — September 17, 2018 (GLOBE NEWSWIRE) - Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces that GrafixPL PRIME™, a human placental membrane that can be stored at a
September 17, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a18-3103318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2018 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction
September 11, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2018 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of incorporation) (Commission
August 8, 2018	10-Q	OSIR / Osiris Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32966 OSIRIS THERAPEUTICS, IN
July 27, 2018	EX-3.4	Articles of Amendment of the Registrant as filed with the State Department of Assessments and Taxation of Maryland on June 28, 2018 (Incorporated herein by reference to Exhibit 3.4 to the Registration Statement on Form 8-A filed by the Registrant with the SEC on July 27, 2018). EX-3.4 2 a18-178401ex3d4.htm EX-3.4 EXHIBIT 3.4 OSIRIS THERAPEUTICS, INC. ARTICLES OF AMENDMENT Osiris Therapeutics, Inc., a Maryland corporation (the “Corporation”), under Title 8 of the Corporations and Associations Article of the Annotated Code of Maryland, hereby certifies to the State Department of Assessments and Taxation of Maryland (the “Department”) that: FIRST: The Corporation desires to
July 27, 2018	EX-3.5	Amended and Restated Bylaws of the Registrant (Incorporated herein by reference to Exhibit 3.5 to the Registration Statement on Form 8-A filed by the Registrant with the SEC on July 27, 2018). EXHIBIT 3.5 OSIRIS THERAPEUTICS, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. PRINCIPAL OFFICE. The principal office of Osiris Therapeutics, Inc., a Maryland corporation (the “Corporation”), in the State of Maryland shall be located at such place as the Board of Directors may designate. Section 2. ADDITIONAL OFFICES. The Corporation may have additional offices, including a princip
July 27, 2018	8-A12B	OSIR / Osiris Therapeutics, Inc. 8-A12B 8-A12B 1 a18-1784018a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Osiris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Maryland 71-0881115 (State of incorporation or organization) (I.R.S. Employer Id
July 25, 2018	SC 13D/A	OSIR / Osiris Therapeutics, Inc. / Friedli Peter - SC 13D/A Activist Investment SC 13D/A 1 a18-176681sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4) Osiris Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68827R 108 (CUSIP Number) Peter Friedli Chollerstrasse 35 6300 Zug, Switzerland Telephone: +41 (4
July 10, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 a18-1709718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2018 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of i
July 2, 2018	EX-10.1	Form of Indemnification and Advancement of Expenses Letter Agreement (Incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant with the SEC on July 2, 2018). EXHIBIT 10.1 [OSIRIS LETTERHEAD] [·], 2018 [NAME] [ADDRESS] RE: Indemnification and Advancement of Expenses Dear [NAME]: Reference is hereby made to the bylaws (the “Bylaws”) of Osiris Therapeutics, Inc. (the “Company”) and to certain indemnification provisions contained in Article XI of the Bylaws which provide for mandatory indemnification, and, without requiring a preliminary determination of t
July 2, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a18-1617128k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2018 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of i
June 28, 2018	8-K	Current Report 8-K 1 a18-1617118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2018 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of (Commission File Number) (
June 4, 2018	EX-99.1	Diane Savoie Osiris Therapeutics, Inc. (443) 545-1834 EX-99.1 2 a18-146361ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Announces Implementation of Prestige LyotechnologySM Preservation Method Allowing Ambient Storage of Living Tissues COLUMBIA, MARYLAND — June 4, 2018 (GLOBE NEWSWIRE) - Osiris Therapeutics, Inc. (OTC Pink: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, a
June 4, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a18-1463618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2018 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of in
May 11, 2018	DEFA14A	OSIR / Osiris Therapeutics, Inc. DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
May 11, 2018	DEF 14A	OSIR / Osiris Therapeutics, Inc. DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 10, 2018	10-Q	OSIR / Osiris Therapeutics, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32966 OS
May 10, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 a18-1331118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2018 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of inc
April 23, 2018	PRE 14A	OSIR / Osiris Therapeutics, Inc. PRE 14A PRE 14A 1 a2235394zpre14a.htm PRE 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box
April 19, 2018	8-K	Other Events 8-K 1 a18-1116718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2018 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of
March 28, 2018	EX-23.1.1	Consent of Ernst & Young LLP (filed herewith). QuickLinks - Click here to rapidly navigate through this document Exhibit 23.1.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 No. 333-199132) pertaining to Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan, (2) Registration Statement (Form S-8 No. 3
March 28, 2018	10-K	OSIR / Osiris Therapeutics, Inc. 10-K (Annual Report) Use these links to rapidly review the document TABLE OF CONTENTS CONSOLIDATED FINANCIAL STATEMENTS INDEX Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 28, 2018	EX-10.5	Director Agreement, dated June 23, 2016, between Osiris Therapeutics, Inc. and Thomas M. Brandt (filed herewith). Exhibit 10.5 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of June 23, 2016 (the “Agreement”), by and between Osiris Therapeutics, Inc., a Maryland corporation (the “Company”), and Thomas M. Brandt, Jr. (the “Director”). WHEREAS, on March 3, 2016, the Company appointed the Director to its Board of Directors, and desires to enter into an agreement with the Director with respect to such appo
March 28, 2018	EX-10.6	Letter Agreement, dated April 17, 2017, between Osiris Therapeutics, Inc. and Linda L. Chang (filed herewith). Exhibit 10.6 April 17, 2017 By email ([email protected]) Linda L. Chang 141 Central Avenue Gaithersburg, MD 20877 Re: Chief Financial Officer, Osiris Therapeutics, Inc. Dear Ms. Chang: We are delighted to extend this offer of employment for the position of Chief Financial Officer of Osiris Therapeutics, Inc. (“Osiris” or “the Company”). Please note that this offer is subject to approval by our Compa
March 28, 2018	EX-32.1.1	Section 1350 Certification of Chief Executive Officer and Chief Financial Officer (filed herewith). QuickLinks - Click here to rapidly navigate through this document Exhibit 32.1.1 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the unde
March 28, 2018	EX-31.2.1	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) (filed herewith). QuickLinks - Click here to rapidly navigate through this document Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Linda L. Chang, certify that: 1. I have reviewed this Annual Report on Form 10-K of Osiris Therapeutics, Inc., the Registrant; 2. Based on my knowledge, this report does not contain any untrue statement of a mater
March 28, 2018	EX-21	List of Subsidiaries. QuickLinks - Click here to rapidly navigate through this document Exhibit 21 LIST OF SUBSIDIARIES The following is a list of subsidiaries of the Company as of December 31, 2017. Name of Subsidiary Jurisdiction of Incorporation or Organization Osiris Therapeutics International GmbH Switzerland QuickLinks Exhibit 21 LIST OF SUBSIDIARIES
March 28, 2018	EX-31.1.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) (filed herewith). QuickLinks - Click here to rapidly navigate through this document Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jason Keefer, certify that: 1. I have reviewed this Annual Report on Form 10-K of Osiris Therapeutics, Inc., the Registrant; 2. Based on my knowledge, this report does not contain any untrue statement of a materia
March 28, 2018	EX-3.2	Articles of Amendment of the Registrant as filed with the State Department of Assessments and Taxation of Maryland on June 10, 2015 (Incorporated herein by reference to Exhibit 3.2 to the Annual Report on Form 10-K filed by the Registrant with the SEC on March 28, 2018). Exhibit 3.2 OSIRIS THERAPEUTICS, INC. ARTICLES OF AMENDMENT OSIRIS THERAPEUTICS, INC., a Maryland corporation (“Corporation”), hereby certifies to the State Department of Assessments and Taxation of Maryland (the “Department”) that: FIRST: The Corporation desires to, and does hereby, amend the charter of the Corporation as currently in effect (the “Charter”) pursuant to Section 2-604 of the MARYLA
March 28, 2018	EX-10.9	Separation and Release Agreement, dated February 9, 2018, between Linda Palczuk and the Company (filed herewith). Exhibit 10.9 EXECUTION COPY SEPARATION AND RELEASE AGREEMENT Osiris Therapeutics, Inc. (“Osiris” or the “Company”) and Linda Palczuk (“You”) enter into this Separation and Release Agreement (“Agreement”) effective as of the Effective Date (as defined below). WHEREAS, Your final day of employment with the Company shall be February 9, 2018 (the “Separation Date”); and WHEREAS, You and Osiris desire
March 16, 2018	NT 10-K	OSIR / Osiris Therapeutics, Inc. NT 10-K NT 10-K 1 a17-289294nt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2017 o Transition Report on Form 10-K o Transition Report on Form 2
February 8, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 a18-569018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2018 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of
February 6, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 a18-548518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2018 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of
December 14, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2017 (December 13, 2017) OSIRIS THERAPEUTICS, INC.
December 5, 2017	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2017 OSIRIS THERAPEUTICS, INC.
November 13, 2017	NT 10-Q	OSIR / Osiris Therapeutics, Inc. 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K
November 3, 2017	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a17-251451ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Therapeutics, Inc. Announces Resolution of SEC Investigation COLUMBIA, MARYLAND. — November 2, 2017 - Osiris Therapeutics, Inc. (OTC Pink: OSIR) (the “Company”), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced the resolution of the previo
November 3, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a17-2514518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2017 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction o
August 10, 2017	NT 10-Q	Osiris Therapeutics NT 10-Q NT 10-Q 1 a17-200321nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F
June 26, 2017	EX-10.1	Employment Agreement, dated June 24, 2017, between Linda Palczuk and the Company (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant with the SEC on June 26, 2017). EX-10.1 2 a17-156971ex10d1.htm EX-10.1 Exhibit 10.1 Execution Copy Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of June 24, 2017, by and between Linda Palczuk (the “Executive”) and Osiris Therapeutics, Inc., a Maryland corporation (“Osiris” or the “Company”). WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth h
June 26, 2017	EX-10.2	Employee Confidentiality, Noncompetition and Invention Agreement, effective July 10, 2017, between Linda Palczuk and the Company. (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant with the SEC on June 26, 2017). EX-10.2 3 a17-156971ex10d2.htm EX-10.2 Exhibit 10.2 Execution Copy EMPLOYEE CONFIDENTIALITY, NONCOMPETITION AND INVENTION AGREEMENT This Agreement effective as of the 10th day of July, 2017 (Effective Date) by and between OSIRIS THERAPEUTICS, INC., a corporation having a place of business at 7015 Albert Einstein Drive, Columbia, Maryland 21046 (hereinafter “Osiris” or the “Company”), and Linda Pal
June 26, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 a17-1569718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2017 (June 21, 2017) OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other j
May 31, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2017 OSIRIS THERAPEUTICS, INC.
May 31, 2017	EX-99.1	Diane Savoie Osiris Therapeutics, Inc. (443) 545-1839 7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Appoints David White to its Board of Directors COLUMBIA, Md. ? May 31, 2017 - Osiris Therapeutics, Inc. (Pink Sheets: OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on May 30th, 2017, appointed Mr. David White as a director, upon recommendation of the Nominating Committee. The Board of Directors also appointed Mr. White as a member of the Audit Com
May 19, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2017 (May 15, 2017) OSIRIS THERAPEUTICS, INC.
May 17, 2017	8-K	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2017 OSIRIS THERAPEUTICS, INC.
May 11, 2017	NT 10-Q	Osiris Therapeutics NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tr
March 27, 2017	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition 8-K 1 a17-995218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2017 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of i
March 27, 2017	EX-23.1.1	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 23.1.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Osiris Therapeutics, Inc. Columbia, Maryland We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-148750) and Forms S-8 (No. 333-137952, 333-137953, 333-167652, 333-184838 and 333-199132) of Osiris Therapeutics, Inc. of our reports dated March 27, 2017, relating to the financi
March 27, 2017	EX-10.9	Exclusive Service Agreement by and between the Registrant and Howmedica Osteonics Corp., also referred to as Stryker Orthopaedics, dated as of December 19, 2014 (Incorporated herein by reference to Exhibit 10.9 to the Annual Report on Form 10-K/A filed by the Registrant with the SEC on March 27, 2017). Exhibit 10.9 EXCLUSIVE SERVICE AGREEMENT THIS EXCLUSIVE SERVICE AGREEMENT, including all appendices hereto and as may be amended from time to time (this “Agreement”), is made and entered into effective as of the 19th day of December, 2014 (the “Effective Date”), by and between Howmedica Osteonics Corp., also referred to as Stryker Orthopaedics (“Stryker”), a New Jersey corporation, having a place
March 27, 2017	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David A. Dresner, certify that: 1. I have reviewed this Annual Report on Form 10-K/A of Osiris Therapeutics, Inc., the Registrant; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make th
March 27, 2017	EX-32.1.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) Exhibit 32.1.1 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Osiris Therapeutics, Inc., (the “Company”), do
March 27, 2017	10-K/A	OSIR / Osiris Therapeutics, Inc. 10-K/A (Annual Report) 10-K/A 1 a16-8011110ka.htm 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ended December 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition perio
March 27, 2017	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Gregory I. Law., certify that: 1. I have reviewed this Annual Report on Form 10-K/A of Osiris Therapeutics, Inc., the Registrant; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
March 27, 2017	EX-10.7	Third Amendment to Agreement of Lease by and between the Registrant and Columbia Gateway S-28, L.L.C., dated September 30, 2014 (Incorporated herein by reference to Exhibit 10.7 to the Annual Report on Form 10-K/A filed by the Registrant with the SEC on March 27, 2017). Exhibit 10.7 THIRD AMENDMENT TO AGREEMENT OF LEASE THIS THIRD AMENDMENT TO AGREEMENT OF LEASE (this “Amendment”) is made this 25th day of September 2014, by COLUMBIA GATEWAY S-28, L.L.C., a Maryland limited liability company (“Landlord”) and OSIRIS THERAPEUTICS, INC., a Maryland corporation (“Tenant”). W I T N E S S E T H: WHEREAS, Landlord and Tenant entered into that Agreement of Lease dated Jun
March 17, 2017	NT 10-K	Osiris Therapeutics NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o
March 10, 2017	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Receives Notice of Delisting from NASDAQ COLUMBIA, Md. ? March 10, 2017 - Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the ?Company?) announced today that the Company received a letter from the NASDAQ Stock Market (?NASDAQ?) stating that trading of the Company?s common stock will be suspended at the opening of business on Tuesday, March 14, 2017. The letter also states that NASDAQ
March 10, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2017 OSIRIS THERAPEUTICS, INC.
February 13, 2017	SC 13G/A	OSIR / Osiris Therapeutics, Inc. / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP Passive Investment SC 13G/A 1 osira121017.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Osiris Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68827R108 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing
February 10, 2017	EX-99.1	Diane Savoie Osiris Therapeutics, Inc. (443) 545-1839 7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a17-40952ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors COLUMBIA, Md. — February 10, 2017 - Osiris Therapeutics, Inc. (NASDAQ: OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on February 7th, 2017, confirmed the appointment of Messrs. Uwe Sommer and Thomas J. Knapp as directors, upon recommendation of the
February 10, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 a17-409528k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2017 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of
January 31, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2017 OSIRIS THERAPEUTICS, INC.
January 12, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 a17-201718k.htm 8-K PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT COMMUNICATION ATTORNEY WORK PRODUCT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2017 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specifie
December 2, 2016	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a16-225741ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Provides Update Regarding NASDAQ Listing Matters COLUMBIA, Md. — December 2, 2016 - Osiris Therapeutics, Inc. (NASDAQ: OSIR) (the “Company”) today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market (“NASDAQ”). As previously disclosed, the Company participated in a hearing before the
December 2, 2016	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a16-2257418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction o
November 21, 2016	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2016 OSIRIS THERAPEUTICS, INC.
November 21, 2016	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a16-219571ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Provides Update Regarding NASDAQ Listing Matters COLUMBIA, Md. — November 21, 2016 - Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market (“NASDAQ”). As previously disclosed, the Company received notifications from NASDAQ in
November 14, 2016	NT 10-Q	Osiris Therapeutics NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K
November 7, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a16-2124918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction o
November 7, 2016	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a16-212491ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Therapeutics, Inc. Reports Preliminary 2014 and 2015 Revenue and Anticipated 2016 Revenue COLUMBIA, Md. — November 7, 2016 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopaedics, and sports medicine, today announced its preliminary revenu
October 14, 2016	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2016 OSIRIS THERAPEUTICS, INC.
October 7, 2016	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2016 OSIRIS THERAPEUTICS, INC.
October 6, 2016	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a16-195981ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Therapeutics Announces Appointment of Alberto Avendano, M.D. as Chief Medical Officer COLUMBIA, Md. — October 6, 2016 - (BUSINESS WIRE) — Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has appointed R. Alberto Avendano, M.D., as the Company’s Chief Medical Officer. Dr. Avendano brings to Osiris his expertise in medical edu
October 6, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2016 OSIRIS THERAPEUTICS, INC.
September 16, 2016	EX-99.1	Osiris Provides Update Regarding NASDAQ Listing Status Company to Request NASDAQ Hearings Panel to Stay NASDAQ Delisting EX-99.1 2 a16-186471ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Provides Update Regarding NASDAQ Listing Status Company to Request NASDAQ Hearings Panel to Stay NASDAQ Delisting COLUMBIA, Md. — September 16, 2016 - Osiris Therapeutics, Inc. (NASDAQ: OSIR) (the “Company”) provided today an update concerning the status of its compliance with the Listing Rules of the NASDAQ Stock Market (“NASDAQ”). As pre
September 16, 2016	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits 8-K 1 a16-1864718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction
August 17, 2016	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits 8-K 1 a16-1685018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of
August 17, 2016	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a16-168501ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Provides Update Regarding NASDAQ Listing Matters COLUMBIA, Md. — August 17, 2016 - Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market (“NASDAQ”). As previously disclosed, on each of March 17, 2016 and May 12, 2016 the Comp
August 9, 2016	NT 10-Q	Osiris Therapeutics NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tra
June 29, 2016	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K/A 1 a16-1421618ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdicti
June 29, 2016	EX-10.1	Letter Agreement, dated June 23, 2016, between Osiris Therapeutics, Inc. and David A. Dresner (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K/A filed by the Registrant with the SEC on June 29, 2016). Exhibit 10.1 June 23, 2016 Mr. David A. Dresner Re: Interim Chief Executive Officer and President Dear Dave: We?re delighted to extend this offer of employment for the position of Interim Chief Executive Officer of Osiris Therapeutics, Inc. If you accept this offer, your employment will start immediately. These are the terms and conditions of your employment if you accept this offer: 1. Position.
June 14, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 a16-1335318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of i
June 10, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 a16-1318818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of in
May 27, 2016	8-K	Osiris Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2016 OSIRIS THERAPEUTICS, INC.
May 16, 2016	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph. 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a16-112751ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Provides Update Regarding NASDAQ Listing Matters COLUMBIA, Md. — May 16, 2016 - Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market (“NASDAQ”). As previously disclosed, on March 17, 2016 the Company received a notification
May 16, 2016	8-K	Osiris Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2016 OSIRIS THERAPEUTICS, INC.
May 11, 2016	NT 10-Q	Osiris Therapeutics NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tr
April 14, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 a16-847418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of i
March 22, 2016	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 a16-702518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of i
March 15, 2016	NT 10-K	Osiris Therapeutics NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o
March 15, 2016	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Other Events 8-K 1 a16-644718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of i
March 9, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 a16-611718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of in
March 9, 2016	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Confirms Dwayne Montgomery, as President and Chief Executive Officer, and the Election of Thomas M. Brandt to the Board of Directors COLUMBIA, Md. ? March 3, 2016 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is ple
February 26, 2016	EX-10.1	Separation and Release Agreement, dated February 22, 2016, between Osiris Therapeutics, Inc. and Lode Debrabandere, Ph.D. (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K/A filed by the Registrant with the SEC on February 26, 2016). Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT Osiris Therapeutics (?Osiris? or the ?Company?) and Lode Debrabandere (?You?) enter into this Separation and Release Agreement (?Agreement?) effective as of the Effective Date (as defined below). WHEREAS, You resigned for personal reasons from your position as Chief Executive Officer (?CEO?) and director of the Company on February 3, 2016; and WHEREAS,
February 26, 2016	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2016 OSIRIS THERAPEUTICS, INC.
February 11, 2016	SC 13G	Osiris Therapeutics CONSONANCE CAPITAL MANAGEMENT LP (Passive Acquisition of More Than 5% of Shares) SC 13G 1 osir21116.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Osiris Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68827R108 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Che
February 3, 2016	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Therapeutics Announces Leadership Transition COLUMBIA, Md. ? February 3, 2016 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Dwayne Montgomery, its current Chief Business Officer, has been appoin
February 3, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 a16-356418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2016 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of
December 17, 2015	8-K	Osiris Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2015 OSIRIS THERAPEUTICS, INC.
December 17, 2015	EX-16.1	Letter from BDO USA, LLP, dated December 17, 2015 (Incorporated by reference to Exhibit 1.1 to the Current Report on Form 8‑K filed by the Registrant with the SEC on December 17, 2015). Exhibit 16.1 Tel: 703-893-0600 Fax: 703-893-2766 www.bdo.com 8401 Greensboro Drive, Suite 800 McLean, VA 22102 December 17, 2015 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on December 11, 2015, to be filed by our former client, Osiris Therapeutics, Inc. We agree
November 20, 2015	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review 8-K 1 a15-2386518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2015 OSIRIS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Maryland 001-32966 71-0881115 (State or other jurisdiction
November 16, 2015	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lode Debrabandere, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2015 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
November 16, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 osir-20150930x10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu
November 16, 2015	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Gregory I. Law., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2015 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f
November 10, 2015	NT 10-Q	Osiris Therapeutics NT 10-Q NT 10-Q 1 a15-179603nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Re
November 6, 2015	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a15-225401ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Therapeutics Announces Third Quarter 2015 Financial Results COLUMBIA, Md. — November 6, 2015 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today its financial results f
November 6, 2015	8-K	Osiris Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2015 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of incorporation) (Commission
September 21, 2015	8-K	Current Report 8-K 1 a15-1995618k.htm 8-K United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2015 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32966 71-0881115 (State or other jurisdiction o
August 10, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a15-12062110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss
August 10, 2015	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philip R. Jacoby, Jr., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2015 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
August 10, 2015	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lode Debrabandere, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2015 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
August 5, 2015	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Therapeutics Announces Second Quarter 2015 Financial Results COLUMBIA, Md. ?August 5, 2015 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today its financial results for the second quarter of 2015. Second Qua
August 5, 2015	8-K	Current Report 8-K 1 a15-1701918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2015 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of in
June 12, 2015	8-K	Osiris Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2015 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of (Commission File Number) (IRS
May 11, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a15-7834110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss
May 11, 2015	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philip R. Jacoby, Jr., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2015 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
May 11, 2015	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lode Debrabandere, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2015 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fac
May 8, 2015	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Therapeutics Announces First Quarter 2015 Financial Results. COLUMBIA, Md. May 8, 2015 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today its financial results for the first quarter of 2015. Highlight
May 8, 2015	8-K	Current Report 8-K 1 a15-1120318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2015 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of incor
April 30, 2015	DEF 14A	Osiris Therapeutics DEF 14A DEF 14A 1 a2224529zdef14a.htm DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box
April 30, 2015	DEFA14A	Osiris Therapeutics DEFA14A DEFA14A 1 a15-14943defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as
April 21, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 a15-945118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2015 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of (Co
April 21, 2015	PRE 14A	Osiris Therapeutics PRE 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 9, 2015	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a15-87541ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Therapeutics Announces Alla Danilkovitch, Ph.D., as Chief Scientific Officer COLUMBIA, Md. — April 9, 2015 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedic and sports medicine markets is pleased to announ
April 9, 2015	8-K	Current Report 8-K 1 a15-875418k.htm 8-K United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2015 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32966 71-0881115 (State or other jurisdiction of inco
April 8, 2015	8-K	Other Events 8-K 1 a15-875428k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2015 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of (Com
March 20, 2015	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 QuickLinks - Click here to rapidly navigate through this document Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philip R. Jacoby, Jr., certify that: 1. I have reviewed this Annual Report on Form 10-K of Osiris Therapeutics, Inc., the Registrant; 2. Based on my knowledge, this report does not contain any untrue statement of
March 20, 2015	EX-23.1.1	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM QuickLinks - Click here to rapidly navigate through this document Exhibit 23.1.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Osiris Therapeutics, Inc. Columbia, Maryland We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-148750) and Forms S-8 (No. 333-167652, 333-137953, 333-184838 and 333-199132) of Osiris Therapeutics, Inc. of our
March 20, 2015	EX-32.1.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) QuickLinks - Click here to rapidly navigate through this document Exhibit 32.1.1 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the unde
March 20, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Use these links to rapidly review the document TABLE OF CONTENTS ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ended December 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
March 20, 2015	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 QuickLinks - Click here to rapidly navigate through this document Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lode Debrabandere, certify that: 1. I have reviewed this Annual Report on Form 10-K of Osiris Therapeutics, Inc., the Registrant; 2. Based on my knowledge, this report does not contain any untrue statement of a ma
March 20, 2015	EX-10.7	THIRD AMENDMENT TO AGREEMENT OF LEASE Exhibit 10.7 THIRD AMENDMENT TO AGREEMENT OF LEASE THIS THIRD AMENDMENT TO AGREEMENT OF LEASE (this “Amendment”) is made this 25th day of September 2014, by COLUMBIA GATEWAY S-28, L.L.C., a Maryland limited liability company (“Landlord”) and OSIRIS THERAPEUTICS, INC., a Maryland corporation (“Tenant”). W I T N E S S E T H: WHEREAS, Landlord and Tenant entered into that Agreement of Lease dated Jun
March 20, 2015	EX-10.9	EXCLUSIVE SERVICE AGREEMENT Exhibit 10.9 EXCLUSIVE SERVICE AGREEMENT THIS EXCLUSIVE SERVICE AGREEMENT, including all appendices hereto and as may be amended from time to time (this “Agreement”), is made and entered into effective as of the 19th day of December, 2014 (the “Effective Date”), by and between Howmedica Osteonics Corp., also referred to as Stryker Orthopaedics (“Stryker”), a New Jersey corporation, having a place
March 17, 2015	NT 10-K	Osiris Therapeutics NT 10-K NT 10-K 1 a14-262334nt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2014 o Transition Report on Form 10-K o Transition Report on Form 2
March 5, 2015	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results: For the Full Year, Revenue Increased 146% and Company Reports Record Revenue in Fourth Quarter. COLUMBIA, Md. ? March 5, 2015 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, o
March 5, 2015	8-K	Osiris Therapeutics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2015 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of incorporation) (Commission Fil
December 24, 2014	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Announces a Strategic Partnership with Stryker for Marketing Osiris’ Viable Bone Matrix COLUMBIA, Md. — December 22, 2014 — Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has entered into an exclu
December 24, 2014	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of (Commission File Number) (
November 26, 2014	8-K	Current Report United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32966 71-0881115 (State or other jurisdiction of (Commission File Number) (
November 19, 2014	8-K	Current Report United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32966 71-0881115 (State or other jurisdiction of (Commission File Number) (
November 10, 2014	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philip R. Jacoby, Jr., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2014 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mate
November 10, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3296
November 10, 2014	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lode Debrabandere, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2014 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
November 7, 2014	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a14-239521ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Therapeutics Announces Third Quarter 2014 Financial Results: Revenue up 29% and Company Turned Profitable COLUMBIA, Md. — November 7, 2014 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedic and sports
November 7, 2014	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of incorporation) (Commission
October 3, 2014	EX-4.5	Second Amendment to Amended & Restated 2006 Omnibus Plan, effective as of May 6, 2014 (Incorporated herein by reference to Exhibit 4.5 to the Registration Statement on Form S-8 filed by the Registrant with the SEC on October 3, 2014). EX-4.5 2 a14-217601ex4d5.htm EX-4.5 Exhibit 4.5 Second Amendment to Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan This SECOND AMENDMENT TO OSIRIS THERAPEUTICS, INC. AMENDED AND RESTATED 2006 OMNIBUS PLAN, of Osiris Therapeutics, Inc., a Maryland corporation (the “Company”), amends the Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan (as previously existing or as
October 3, 2014	S-8	OSIR / Osiris Therapeutics, Inc. S-8 - - S-8 S-8 1 a14-217601s8.htm S-8 As filed with the Securities and Exchange Commission on October 3, 2014 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OSIRIS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Maryland 71-0881115 (State or other jurisdiction of (I.R.S. Employ
October 2, 2014	8-K	Current Report United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32966 71-0881115 (State or other jurisdiction of (Commission File Number)
August 11, 2014	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philip R. Jacoby, Jr., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2014 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
August 11, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 o TRANSITION REPORT PURSUANT TO S 10-Q 1 a14-14047110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss
August 11, 2014	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lode Debrabandere, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2014 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
August 7, 2014	8-K	8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of incorporation) (Commission Fi
August 7, 2014	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 2 a14-186221ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Therapeutics Announces Second Quarter 2014 Financial Results: Revenue Up 32% Over Previous Quarter COLUMBIA, Md. — August 7, 2014 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced today its financial results
May 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a14-9603110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss
May 12, 2014	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lode Debrabandere, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2014 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fac
May 12, 2014	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philip R. Jacoby, Jr., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2014 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
May 12, 2014	8-K	Current Report 8-K 1 a14-1257418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of inco
May 12, 2014	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Reports First Quarter 2014 Results: Revenue Up 25% and Gross Margin Improved from 73% to 78% COLUMBIA, Md. — May 12, 2014 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced today its financial results for the first quarter of 2014. Highlights and R
May 8, 2014	8-K	Current Report 8-K 1 a14-1218018k.htm 8-K United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of (Comm
April 4, 2014	8-K	Current Report United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32966 71-0881115 (State or other jurisdiction of (Commission File Number) (IRS
March 31, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K 10-K 1 a2219393z10-k.htm 10-K Use these links to rapidly review the document TABLE OF CONTENTS ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ended December 31, 2013 o TRANSITION REPORT P
March 31, 2014	EX-32.1.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) QuickLinks - Click here to rapidly navigate through this document Exhibit 32.1.1 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the unde
March 31, 2014	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 QuickLinks - Click here to rapidly navigate through this document Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lode Debrabandere, certify that: 1. I have reviewed this Annual Report on Form 10-K of Osiris Therapeutics, Inc., the Registrant; 2. Based on my knowledge, this report does not contain any untrue statement of a ma
March 31, 2014	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 QuickLinks - Click here to rapidly navigate through this document Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philip R. Jacoby, Jr., certify that: 1. I have reviewed this Annual Report on Form 10-K of Osiris Therapeutics, Inc., the Registrant; 2. Based on my knowledge, this report does not contain any untrue statement of
March 31, 2014	EX-23.1.1	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM QuickLinks - Click here to rapidly navigate through this document Exhibit 23.1.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Osiris Therapeutics, Inc. Columbia, Maryland We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-148750) and Forms S-8 (No. 333-167652, 333-137953 and 333-184838) of Osiris Therapeutics, Inc. of our reports dat
March 31, 2014	EX-10.7	CONFIDENTIAL PURCHASE AGREEMENT by and between MESOBLAST INTERNATIONAL SÀRL OSIRIS THERAPEUTICS, INC. DATED AS OF OCTOBER 10, 2013 EX-10.7 2 a2219393zex-107.htm EX-10.7 Exhibit 10.7 CONFIDENTIAL PURCHASE AGREEMENT by and between MESOBLAST INTERNATIONAL SÀRL (“MSB”) and OSIRIS THERAPEUTICS, INC. (“OTI”) DATED AS OF OCTOBER 10, 2013 TABLE OF CONTENTS PAGE ARTICLE 1 Definitions / Interpretation 1 1.1 Certain Definitions 1 1.2 Certain Additional Definitions 13 1.3 Interpretation 14 ARTICLE 2 Purchase and Sale 15 2.1 Purchase and
March 28, 2014	DEF 14A	- DEF 14A DEF 14A 1 a2219320zdef14a.htm DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box
March 28, 2014	DEFA14A	- DEFA14A DEFA14A 1 a14-23903defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as
March 17, 2014	NT 10-K	- NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-32966 CUSIP Number: 68827R 10 8 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2013 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o
March 11, 2014	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Therapeutics Reports Change in Tax Benefit Allocation for Fourth Quarter and Full Year 2013 Financial Results No Change in Net Income, Cash or Cash Flow COLUMBIA, Md. — March 11, 2014 - Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today an accounting adjustment to its Fourth Quarter and Full Year 2013 financial results reported on March 5. The adjustment results from a ch
March 11, 2014	8-K/A	Current Report 8-K/A 1 a14-777718ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction
March 5, 2014	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Therapeutics Reports Full Year 2013 and Fourth Quarter Financial Results: For the Full Year, Revenue Increased 3-Fold, Company was Profitable and Ended with Assets of $92.0 Million COLUMBIA, Md. — March 5, 2014 - Osiris Therapeutics, Inc. (NASDAQ: OSIR) the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and s
March 5, 2014	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of incorporation) (Commission Fil
February 12, 2014	8-K	Current Report 8-K 1 a14-572218k.htm 8-K United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32966 71-0881115 (State or other jurisdiction of (
January 15, 2014	8-K	- 8-K United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2014 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32966 71-0881115 (State or other jurisdiction of (Commission File Number) (I
December 6, 2013	8-K	Current Report United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2013 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32966 71-0881115 (State or other jurisdiction of (Commission File Number) (I
November 12, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 o TRANSITION REPORT PURSUANT 10-Q 1 a13-19541110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co
November 12, 2013	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philip R. Jacoby, Jr., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2013 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mate
November 12, 2013	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, C. Randal Mills, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2013 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f
November 1, 2013	8-K	Current Report 8-K 1 a13-2325918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2013 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of
November 1, 2013	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Reports 3rd Quarter 2013 Results: Revenue Up 220%, Strong Balance Sheet, Profitable and Now Cash Flow Positive from Continuing Operations COLUMBIA, Md. — November 1, 2013 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in the orthopedic, sports medicine and wound care markets announced today its financial re
October 24, 2013	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Corrects Certain Inaccuracies in Media Reports COLUMBIA, Md. — October 24, 2013 — Osiris Therapeutics, Inc. (NASDAQ: OSIR), issued a statement today correcting certain inaccuracies in media reports following the announcement of its favorable agreement with the United States Food and Drug Administration (FDA) regarding Grafix®. · Grafix is and will continue to be available on th
October 24, 2013	8-K	Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2013 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of incorporation) (Commission
October 21, 2013	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris and FDA Reach Agreement on Regulatory Pathway for Biosurgery Products COLUMBIA, Md. — October 21, 2013 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that it has reached agreement with the United States Food and Drug Administration (FDA) regarding the regulatory pathway for its Biosurgery products, Grafix® and Ovation®. After discussions with the FDA, the regulator
October 21, 2013	8-K	Regulation FD Disclosure 8-K 1 a13-2254718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2013 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of
October 21, 2013	EX-99.2	DEPARTMENT OF HEALTH & HUMAN SERVICES Exhibit 99.2 DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Center for Biologics Evaluation and Research 1401 Rockville Pike Rockville, MD 20852-1448 September 26, 2013 VIA FACSIMILE AND UPS C. Randall Mills, PhD Chief Executive Officer Osiris Therapeutics, Inc. 7015 Albert Einstein Drive Columbia, MD 21046-1707 Dear Dr. Mills: During an inspection of your firm, Osiris Therapeu
October 11, 2013	EX-9.1	UNAUDITED PRO FORMA FINANCIAL INFORMATION EXHIBIT 9.1 UNAUDITED PRO FORMA FINANCIAL INFORMATION The following unaudited pro forma financial statements give effect to the sale of assets contemplated by the purchase agreement and the related transaction documents. The unaudited pro forma balance sheet and statements of operations filed with this report are presented for illustrative purposes only. The pro forma balance sheet as of June 30,
October 11, 2013	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com EX-99.1 3 a13-221261ex99d1.htm EX-99.1 Exhibit 99.1 Osiris Announces Agreement for Culture-Expanded MSCs including Prochymal Worth Up To $100 Million Plus Royalties COLUMBIA, Md. – October 10, 2013 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that it has entered into an agreement with a wholly-owned subsidiary of Mesoblast Limited (ASX:MSB; USOTC:MBLTY) for the sale of Osiris’ cultu
October 11, 2013	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 a13-2212618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2013 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of
September 25, 2013	EX-16.1	[LETTERHEAD OF GRANT THORNTON LLP] EX-16.1 2 a13-212281ex16d1.htm EX-16.1 Exhibit 16.1 [LETTERHEAD OF GRANT THORNTON LLP] September 25, 2013 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: Osiris Therapeutics, Inc. File No. 001-32966 Dear Sir or Madam: We have read Item 4.01 of Form 8-K of Osiris Therapeutics, Inc. dated September 25, 2013, and agree with the statemen
September 25, 2013	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2013 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of (Commission File Number)
August 13, 2013	EX-99.1	Top-Line Data from the Interim Analysis of Protocol 302 Exhibit 99.1 Grafix® Demonstrates Overwhelming Efficacy in Landmark Stem Cell Study for the Treatment of Diabetic Foot Ulcers Grafix closes three times as many wounds as standard of care - the largest relative improvement ever reported in a multi-center, randomized, controlled clinical trial for DFU COLUMBIA, Md. - August 13,2013 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), reported today that its
August 13, 2013	8-K	Current Report 8-K 1 a13-1854418k.htm 8-K United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2013 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Maryland 001-32966 71-0881115 (State or other jurisdiction of (
August 9, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a13-13627110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss
August 9, 2013	EX-31.2.1	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.2.1 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philip R. Jacoby, Jr., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2013 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
August 9, 2013	EX-31.1.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31.1.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, C. Randal Mills, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2013 of Osiris Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact n
August 5, 2013	EX-99.1	7015 Albert Einstein Drive · Columbia, Maryland 21046 · Ph 443.545.1800 · Fax 443.545.1701 · www.Osiris.com Exhibit 99.1 Osiris Therapeutics Announces Second Quarter 2013 Financial Results COLUMBIA, Md. — August 5, 2013 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter of 2013. Highlights

OSIR / Osiris Therapeutics, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)